These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18700899)

  • 1. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
    Sawaki A; Kanemitsu Y; Mizuno N; Takahashi K; Nakamura T; Ioka T; Tanaka S; Nakaizumi A; Salem AA; Ueda R; Yamao K
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 1):1292-7. PubMed ID: 18700899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
    Maréchal R; Demols A; Gay F; De Maertelaere V; Arvanitaki M; Hendlisz A; Van Laethem JL
    Oncology; 2007; 73(1-2):41-51. PubMed ID: 18334830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.
    Morizane C; Okusaka T; Morita S; Tanaka K; Ueno H; Kondo S; Ikeda M; Nakachi K; Mitsunaga S
    Pancreas; 2011 Apr; 40(3):415-21. PubMed ID: 21283041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
    N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
    Otake A; Tsuji D; Taku K; Kawasaki Y; Yokoi M; Nakamori H; Osada M; Matsumoto M; Inoue K; Hirai K; Itoh K
    Eur J Clin Pharmacol; 2017 Aug; 73(8):1033-1039. PubMed ID: 28487999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
    Nakachi K; Furuse J; Ishii H; Suzuki E; Yoshino M
    Jpn J Clin Oncol; 2007 Feb; 37(2):114-20. PubMed ID: 17272317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
    Xie H; Jiang W; Xiao SY; Liu X
    J Histochem Cytochem; 2013 Feb; 61(2):148-55. PubMed ID: 23124118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
    Park I; Choi SJ; Kim YS; Ahn HK; Hong J; Sym SJ; Park J; Cho EK; Lee JH; Shin YJ; Shin DB
    Cancer Res Treat; 2016 Oct; 48(4):1264-1273. PubMed ID: 27034148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
    Kuroda T; Kumagi T; Yokota T; Seike H; Nishiyama M; Imai Y; Inada N; Shibata N; Imamine S; Okada S; Koizumi M; Yamanishi H; Azemoto N; Miyaike J; Tanaka Y; Tatsukawa H; Utsunomiya H; Ohno Y; Miyake T; Hirooka M; Furukawa S; Abe M; Ikeda Y; Matsuura B; Hiasa Y; Onji M;
    BMC Gastroenterol; 2013 Aug; 13():134. PubMed ID: 24256464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
    An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
    Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
    Tanaka T; Ikeda M; Okusaka T; Ueno H; Morizane C; Hagihara A; Iwasa S; Kojima Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):755-61. PubMed ID: 18845521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
    Goulart BH; Clark JW; Lauwers GY; Ryan DP; Grenon N; Muzikansky A; Zhu AX
    J Hematol Oncol; 2009 Mar; 2():13. PubMed ID: 19291303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.
    Wendling T; Mistry H; Ogungbenro K; Aarons L
    Cancer Chemother Pharmacol; 2016 May; 77(5):927-38. PubMed ID: 26940939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
    Yi JH; Lee J; Park SH; Lee KT; Lee JK; Lee KH; Choi DW; Choi SH; Heo JS; Lim DH; Park YS; Lim HY; Kang WK; Park K; Park JO
    Oncology; 2011; 80(3-4):175-80. PubMed ID: 21701231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
    Fujino Y; Ueda T; Kamigaki T; Takase S; Ajiki T; Kamoda Y; Matsumoto I; Yasuda T; Kuroda Y
    Pancreas; 2007 Apr; 34(3):335-9. PubMed ID: 17414056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
    Ziske C; Schlie C; Gorschlüter M; Glasmacher A; Mey U; Strehl J; Sauerbruch T; Schmidt-Wolf IG
    Br J Cancer; 2003 Oct; 89(8):1413-7. PubMed ID: 14562009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
    Inal A; Ciltas A; Yildiz R; Berk V; Kos FT; Dane F; Unek IT; Colak D; Ozdemir NY; Buyukberber S; Gumus M; Ozkan M; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(5):1841-4. PubMed ID: 22901133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.